Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$18.59 USD
+0.10 (0.54%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.58 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.59 USD
+0.10 (0.54%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.58 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Zacks News
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
by Zacks Equity Research
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
by Zacks Equity Research
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week
by Zacks Equity Research
Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.
Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag
by Zacks Equity Research
The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. The stock gains 2.3% following the news.
Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 170.9% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to an 183.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 211.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Sell Stocks for March 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
5 Medical Outperformers That Might Lose Steam in 2021
by Zacks Equity Research
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.
Rocket Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rocket Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Why Rocket (RCKT) Stock Might be a Great Pick
by Zacks Equity Research
Rocket (RCKT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Rocket Pharmaceuticals (RCKT) have what it takes to be a top stock pick for momentum investors? Let's find out.